52 Week Range
As of on the New York Stock Exchange ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
GSK Appoints Brian Mcnamara As CEO Designate Of New Consumer Healthcare Co
Sanofi: rolling reviews of COVID-19 recombinant vaccine to start soon in UK, Canada and Singapore
EU Drugs Regulator Starts Rolling Review Of Sanofi/GSK COVID-19 Vaccine
GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. It has a portfolio of medicines in respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines.
G S K House, 980 Great West Road
Jonathan Richard Symonds
Independent Non-Executive Chairman of the Board
Emma N. Walmsley
Chief Executive Officer, Executive Director
Iain James Mackay
Chief Financial Officer, Executive Director
Roger G. Connor
President - Global Vaccines
Chief Executive Officer - GSK Consumer Healthcare
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
* GLAXOSMITHKLINE PLC - CEO DESIGNATE OF NEW CONSUMER HEALTHCARE COMPANY
Europe's drug regulator said on Tuesday it had started a real-time review of the COVID-19 vaccine developed by French drugmaker Sanofi and Britain's GlaxoSmithKline, the fifth shot currently under such a review.
* GSK-VIIV HEALTHCARE STUDY SHOWS NEW LONG-ACTING HIV REGIMEN CABENUVA CAN BE USED IN BROAD RANGE OF US HEALTHCARE PRACTICES, EVEN DURING COVID-19 Source text for Eikon: Further company coverage:
GSK said on Friday its anaemia drug for patients with kidney disease succeeded in late-stage trials, marking an important milestone for the British drugmaker as it bolsters its pipeline ahead of a split with its consumer healthcare venture.
* GLAXOSMITHKLINE PLC - GSK ANNOUNCES DAPRODUSTAT PHASE 3 HEADLINE RESULTS
Britain's GlaxoSmithKline on Friday laid out plans to set up a new life sciences campus within its R&D site in Stevenage, England, raising up to 400 million pounds ($552.76 million) by selling some land at the facility.
* GSK - UNVEILS PLAN FOR ONE OF EUROPE'S LARGEST LIFE SCIENCE CAMPUSES IN STEVENAGE
Italy approved the temporary distribution of a coronavirus antibody treatment by Britain's GlaxoSmithKline and U.S. company Vir Biotechnology, the health ministry said in a statement on Tuesday.
Sanofi SA and GlaxoSmithKline Plc have received an approval from Indian authorities for a late-stage clinical trial of their protein-based COVID-19 vaccine candidate, the drugmakers said on Thursday.
GlaxoSmithKline Plc and U.S. firm Alector Inc will together develop antibody-based treatments for Parkinson's, Alzheimer's and other similar diseases in a deal worth up to $2.2 billion, the drugmakers said on Friday.
* GSK - NOTES LETTER ISSUED BY ELLIOTT ADVISORS (UK) LIMITED ("ELLIOTT") ON 1 JULY
Activist investor Elliott said GlaxoSmithKline should review its leadership and consider a sale of its consumer healthcare business as it confirmed on Thursday that it had taken a significant stake in the British pharmaceuticals group.
* BELIEVES GSK HAS SUBSTANTIAL VALUE CREATION OPPORTUNITY-45% UPSIDE IN ITS SHARE PRICE-AHEAD OF CONSUMER HEALTH SEPARATION AND GREATER BEYOND
French drugmaker Sanofi on Monday said it agreed to sell 16 mainly European consumer healthcare brands to private-equity owned Stada to streamline its product portfolio.
GlaxoSmithKline Plc has hired two banks to help advise it on listing its consumer unit next year and on defense against a potential activist campaign from Elliott Investment Management, Bloomberg News reported https://www.bloomberg.com/news/articles/2021-06-25/glaxosmithkline-said-to-tap-goldman-citi-for-spinoff...
Britain's FTSE 100 rose on Thursday, led by mining and healthcare-related stocks as the Bank of England kept its crisis-era monetary policy unchanged, while cruise operator Carnival fell after a quarterly loss of over $2 billion.
London's FTSE 100 marked time ahead of the Bank of England's rate decision on Thursday, while GlaxoSmithKline rose on plans to spin off its healthcare arm.
* GLAXOSMITHKLINE PLC - GSK TO DELIVER STEP-CHANGE IN GROWTH & PERFORMANCE
* GLAXOSMITHKLINE PLC - VIIV/HALOZYME SIGN EXCLUSIVE LICENSING AGREEMENT
GlaxoSmithKline Plc and Vir Biotechnology said on Monday final results from a late-stage study of their monoclonal antibody confirmed it significantly reduced hospitalization and death among high-risk COVID-19 patients when given early in the disease.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.